Kidney Cancer Clinical Trial

Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy

Summary

After partial nephrectomy, kidney function decreases by about 10% overall and by about 20% in the operated kidney. This is primarily due to the loss of healthy parenchymal volume during resection of the tumor. In an effort to preserve and regenerate healthy parenchyma during the procedure and ultimately renal function after partial nephrectomy, the single center double arm single-blinded randomized screening clinical trial will evaluate the ability of human amnion/chorion allograft to facilitate the recovery of renal function following robotic partial nephrectomy.

View Full Description

Full Description

To determine whether Amniofix facilitates improved recovery of renal function at 12 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Any individual with a diagnosis of a renal mass.
All Patients undergoing partial nephrectomy as their definitive treatment for their renal mass.
Ability to understand and the willingness to sign a written informed consent.
Patients with a solitary clinical T1a renal mass.

Exclusion Criteria:

Patients undergoing radical nephrectomy as their definitive treatment for their renal mass.
Patients with Transitional Cell Carcinoma.
Patients with known hereditary syndromes such Von Hippel-Lindau (VHL) syndrome, Lynch Syndrome, Birt-Hogg-Dube Syndrome.
Patients with metastatic disease undergoing cytoreductive nephrectomy as their definitive treatment for metastatic disease.
Patients with prior kidney surgery.
Patients with a solitary or horseshoe kidney.
Patients with a positive margin found during intra-operative frozen section done only when clinically indicated (i.e., macroscopic abnormality identified).
Patients with multiple renal masses.
Patients with greater than a clinical T1a renal mass.

Study is for people with:

Kidney Cancer

Estimated Enrollment:

61

Study ID:

NCT03323021

Recruitment Status:

Completed

Sponsor:

MiMedx Group, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

The Mount Sinai Hospital
New York New York, 10029, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

61

Study ID:

NCT03323021

Recruitment Status:

Completed

Sponsor:


MiMedx Group, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider